A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia

Pediatric Transplantation

Volumn 12, Issue 8, 2008, Pages 862-867

  Yabe, Miharu ^a   Sako, Masahiro ^b   Yabe, Hiromasa ^a   Osugi, Yuko ^b   Kurosawa, Hidemitsu ^c   Nara, Taemi ^d   Tokuyama, Mika ^e   Adachi, Souichi ^f   Kobayashi, Chie ^g   Yanagimachi, Masakatsu ^h   Ohtsuka, Yoshitoshi ⁱ   Nakazawa, Yozo ^j   Ogawa, Chitose ^k   Manabe, Atsushi ^k   Kojima, Seiji ^l   Nakahata, Tatsutoshi ^f  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^e TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KYOTO UNIVERSITY   (Japan)

^g Ibaraki Children's Hospital   (Japan)

^h YOKOHAMA CITY UNIVERSITY   (Japan)

ⁱ HYOGO COLLEGE OF MEDICINE   (Japan)

^j SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^l NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Fludarabine containing regimen; Hematopoietic stem cell transplantation; Juvenile myelomonocytic leukemia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; MERCAPTOPURINE; MITOXANTRONE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW CELL; CANCER REGRESSION; CANCER RELAPSE; CARDIOTOXICITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; GRAFT FAILURE; HEMORRHAGIC CYSTITIS; HUMAN; INFANT; INTERSTITIAL PNEUMONIA; JUVENILE MYELOMONOCYTIC LEUKEMIA; LIVER VEIN OBSTRUCTION; LOW DRUG DOSE; MALE; MEDICAL DOCUMENTATION; MONOTHERAPY; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; PILOT STUDY; PRESCHOOL CHILD; SURVIVAL RATE; TREATMENT OUTCOME; UMBILICAL CORD BLOOD;

ADMINISTRATION, ORAL; BUSULFAN; CHILD; CHILD, PRESCHOOL; FEMALE; HISTORY, ANCIENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MALE; MELPHALAN; PILOT PROJECTS; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 54849415692     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.00931.x     Document Type: Article

References (21)

1. Niemeyer CM, Aricò M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: A report of 110 cases. Blood 1997 : 89 : 3534 3543.
2. Manabe A, Okamura J, Yumura-Yagi K, et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 2002 : 16 : 645 649.
3. Smith FO, King R, Nelson G, et al. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukemia. Br J Haematol 2002 : 116 : 716 724.
4. Locatelli F, Nöllke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): Results of the EWG-MDS/EBMT trial. Blood 2005 : 105 : 410 419.
5. Matthes-Martin S, Mann G, Peters C, et al. Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: A single center experience and review of the literature. Bone Marrow Transplant 2000 : 26 : 377 382.
6. Korthof ET, Snijder PP, De Graaff AA, et al. Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: A single center experience of 23 patients. Bone Marrow Transplant 2005 : 35 : 455 461.
7. Niemeyer CM, Fenu S, Hasle H, Mann G, Stary J, Van Wering E. Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood 1998 : 91 : 365 367.
8. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative disease. Leukemia 2003 : 17 : 277 282.
9. Keating M, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998 : 92 : 1165 1171.
10. Virchis A, Koh M, Rankin P, et al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukemia and myelodysplastic syndrome. Br J Haematol 2004 : 124 : 26 32.
11. Fleischhack G, Hasan C, Graf N, Mann G, Bode U. Ida-FLAG (idarubicin, fludarabine, cytarabine, G-CSF) an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologus bone marrow transplantation: Experiences of a phase II trial. Br J Haematol 1998 : 102 : 647 655.
12. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001 : 97 : 631 637.
13. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997 : 337 : 373 381.
14. Bradley MB, Satwani P, Baldinger L, et al. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant 2007 : 40 : 621 631.
15. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998 : 91 : 756 763.
16. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and post grafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological disease. Blood 2003 : 101 : 1620 1629.
17. Georgiani G, Bozzola M, Locatelli F, et al. Role of busulfan and total body irradiation on growth of pre-pubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. Blood 1995 : 86 : 825 831.
18. Socie G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000 : 18 : 348 357.
19. Koyama M, Nakano T, Takeshita Y, et al. Successful treatment of JMML with related bone marrow transplantation after reduced-intensity conditioning. Bone Marrow Transplant 2005 : 36 : 453 454.
20. Locatelli F, Niemeyer C, Angelucci E, et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: A report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol 1997 : 15 : 566 573.
21. Yoshimi A, Mohamed M, Bierings M, et al. Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia 2007 : 21 : 556 560.